09/10/2020 ADO09, a co-formulation of amylin analog pramlintide and human insulin analog A21G, reduces postprandial blood sugar compared to insulin lispro in type 1 diabetes, Dr.  Grégory Meiffren, September 10, 2020, Société Francophone du Diabète, Virtual Event.
09/08/2020 Number of shares and voting rights of ADOCIA as of August 31, 2020 Icon check
09/07/2020 September 15th: Adocia to Present at H.C. Wainwright Global Investment Conference (Virtual Event) Icon check
09/05/2020 ADO09, A Co-Formulation of the Amylin-Analog Pramlintide and the A21G Human Insulin Analog, Lowers Postprandial Blood Glucose versus Insulin Lispro in Type 1 Diabetes (T1D) presented by Dr. Gregory Meiffren, 2020, ATTD, virtual experience. Icon check
09/03/2020 September 10th: Adocia Oral Presentation at the Annual Congress of the Société Francophone du Diabète (SFD). Icon check
08/25/2020 Number of shares and voting rights of ADOCIA as of July 31, 2020 Icon check
08/18/2020 Adocia was granted a State-guaranteed loan (PGE) for EUR 7 million associated with a rescheduling of the loan terms contracted in 2019. Icon check
07/30/2020 Adocia initiates BioChaperone® Lispro comparative study to validate THDB insulin lispro for Phase 3 BC Lispro trials in Europe and U.S Icon check
07/20/2020 Adocia Announces First Half 2020 Financial Results Icon check
07/06/2020 Number of shares and voting rights of ADOCIA as of June 30, 2020 Icon check
06/16/2020 ADO09, a coformulation of pramlintide (PRAM) and insulin A21G, improves postprandial glucose vs. Novolog(R) in Type 1 Diabetes (T1D), Dr. Gregory Meiffren, June 12-16, 2020, ADA virtual experience.
06/16/2020 ADO09, a Coformulation of Pramlintide (PRAM) and Insulin A21G, Improves Postprandial Glucose vs. Novolog in Type 1 Diabetes (T1D) (Poster # 2020-LB-7039-Diabetes), presented by Dr. Gregory Meiffren, June 12-16, 2020, ADA virtual experience. Icon check
06/16/2020 ADO09, a coformulation of pramlintide (PRAM) and insulin A21G, improves postprandial glucose vs. Novolog(R) in Type 1 Diabetes (T1D), Dr. Gregory Meiffren, June 12-16, 2020, ADA virtual experience.
06/08/2020 Adocia Announces M1Pram Clinical Data Presentation at the American Diabetes Association® 80th Scientific Sessions – Virtual experience Icon check
06/05/2020 Number of shares and voting rights of ADOCIA as of May 31, 2020 Icon check
06/03/2020 ADO09, A Co-Formulation of the Amylin-Analog Pramlintide and the A21G Human Insulin Analog, Lowers Postprandial Blood Glucose versus Insulin Lispro in Type 1 Diabetes (T1D) presented by Dr. Gregory Meiffren, 2020, ATTD, virtual experience. Icon check
05/11/2020 Number of shares and voting rights of ADOCIA as of April 30, 2020 Icon check
04/23/2020 Adocia announces positive topline results of the exploratory Phase 1b study of ADO09 (M1Pram) in people with type 1 diabetes Icon check
04/23/2020 Adocia announces the release of its Universal Reference Document for the year 2019 Icon check
04/20/2020 Adocia to hold its annual shareholders’ meeting on May 28th, 2020 in Lyon Icon check
04/14/2020 Adocia announces first quarter 2020 financial results and update on the impact of COVID-19 Icon check
04/09/2020 Number of shares and voting rights of ADOCIA as of March 31, 2020 Icon check
03/12/2020 Adocia Announces Full Year 2019 Financial Results Icon check
03/05/2020 Number of shares and voting rights of ADOCIA as of February 28, 2020 Icon check
02/21/2020 “BioChaperone® Combo, A Co-Formulation Of Lispro And Glargine, Improves Postprandial Glucose Control Compared To Lispromix25 Or Lispro And Glargine Injections In Type 2 Diabetes Subjects” (EPO2 E-Poster Viewing), presented by Dr. Grégory Meiffren, February 21, 2019, ATTD, Berlin (Germany) Icon check
01/07/2020 Number of shares and voting rights of ADOCIA as of December 31, 2019 Icon check
12/17/2019 Adocia announces its financial calendar for 2020 Icon check
12/11/2019 Adocia Announces the Subscription of the Second Tranche of the Financing Line obtained from IPF Partners Icon check
12/06/2019 Number of shares and voting rights of ADOCIA as of November 30, 2019 Icon check
11/07/2019 Number of shares and voting rights of ADOCIA as of October 31st, 2019 Icon check
10/22/2019 Adocia Announces Third Quarter 2019 Financial Results Icon check
10/14/2019 Adocia obtains additional financial resources to accelerate its growth Icon check
10/04/2019 Number of shares and voting rights of ADOCIA as of September 30, 2019 Icon check
09/30/2019 Adocia Announces Receipt of USD 14.3 million Payment from Eli Lilly Following Arbitration Conclusion and the Decision by Mutual Consent with Eli Lilly to Conclude the Civil Case Icon check
09/10/2019 Adocia Announces Oral Presentation Covering ADO09, its pramlintide insulin coformulation, at EASD Icon check
09/09/2019 Number of shares and voting rights of ADOCIA as of August 31, 2019 Icon check
08/23/2019 Adocia announces the decision of the American Arbitration Association Tribunal Icon check
08/06/2019 Number of shares and voting rights of ADOCIA as of July 31st 2019 Icon check
07/17/2019 Adocia Presents First Half 2019 Financial Results Icon check
07/05/2019 Number of shares and voting rights of ADOCIA as of June 30, 2019 Icon check
06/11/2019 Number of shares and voting rights of ADOCIA as of May 31, 2019 Icon check
06/10/2019 “BioChaperone Glucagon Exenatide (BC Glu Exe), a Stable Combination of Glucagon (Glu) and Exenatide (Exe) Achieved Larger Body Weight (BW) Loss than Exe Alone in DIO Mice” (Poster), Author Dr. Martin Gaudier, June 10, 2019, ADA, San Francisco (USA) Icon check
06/09/2019 BioChaperone pramlintide insulin (BCPramIns), a new co-formulation of pramlintide (pram) and human insulin (ins), improves post-prandial blood glucose versus both separate injections of pram+ins and insulin lispro (lis) in subjects with T1D”, Dr. Grégory Meiffren, June 9th, 2019, ADA, San Francisco (USA)
06/09/2019 BioChaperone pramlintide insulin (BCPramIns), a new co-formulation of pramlintide (pram) and human insulin (ins), improves post-prandial blood glucose versus both separate injections of pram+ins and insulin lispro (lis) in subjects with T1D”, Dr. Grégory Meiffren, June 9th, 2019, ADA, San Francisco (USA)
06/06/2019 Adocia initiates a 3-week Phase 1b study of ADO09, a co-formulation of pramlintide and mealtime insulin, in people with type 1 diabetes Icon check
06/04/2019 Adocia Announces Scientific Data Presentations at the American Diabetes Association® 79th Scientific Sessions Icon check
05/07/2019 Number of shares and voting rights of ADOCIA as of April 30, 2019 Icon check
04/15/2019 Article : Grégory Meiffren PhD, Theresa Herbrand MD, Ernestos Anastassiadis MD, Oliver Klein MD, J. Hans DeVries MD, Tim Heise MD, Bertrand Alluis PhD, Claire Mégret PhD, Martin Gaudier PhD, Olivier Soula PhD, Leona Plum‐Mörschel MD.
“Better glycemic control with BioChaperone® Combo (BC Combo) than with insulin lispro Mix25 (LMix) or separate glargine & lispro (G+L) administrations after a test meal in subjects with type 2 diabetes (T2DM)”
Diabetes Obes Metab., 2019;21(7):15701575. Icon check
04/15/2019 Adocia announces the release of its Reference Document for the year 2018 Icon check
04/15/2019 Adocia announces first quarter 2019 financial results: cash position and revenue Icon check
04/10/2019 Adocia announces topline results for the first clinical study of ADO09, a new co-formulation of pramlintide and a prandial insulin Icon check
04/10/2019 Adocia to hold its annual shareholders’ meeting on May 16, 2019 in Paris Icon check
04/08/2019 Better glycaemic control with BioChaperone glargine lispro co-formulation than with insulin lispro Mix25 or separate glargine and lispro administrations after a test meal in people with type 2 diabetes. Diabetes Obes Metab., 2019;21(7):15701575. Icon check
04/04/2019 Number of shares and voting rights of ADOCIA as of March 31, 2019 Icon check
04/03/2019 Heise T, Meiffren G, Alluis B, Seroussi C, Ranson A, Arrubla J, Correia J, Gaudier M, Soula O, Soula R, DeVries JH, Klein O, Bode BW.
“BioChaperone Lispro versus faster aspart and insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: A randomized euglycemic clamp study.”
Diabetes Obes Metab., 2019;21(4):1066-1070. Icon check
03/27/2019 Comparaison des profils pharmacocinétiques et de pharmacodynamie de l’insuline ultra rapide BioChaperone® Lispro avec les formulations Fiasp® et Novorapid® de l’insuline asparte administrées par pompes à insuline, Dr. Grégory Meiffren, March 27, 2019, Annual Congress of the Francophone of the Diabetes Society, Marseille (France)
03/27/2019 Comparaison des profils pharmacocinétiques et de pharmacodynamie de l’insuline ultra rapide BioChaperone® Lispro avec les formulations Fiasp® et Novorapid® de l’insuline asparte administrées par pompes à insuline, Dr. Grégory Meiffren, March 27, 2019, Annual Congress of the Francophone of the Diabetes Society, Marseille (France)
03/26/2019 “BioChaperone Combo, une combinaison fixe d’insuline lispro et d’insuline glargine, améliore les profils de glycémie postprandiale par rapport à un premix d’insuline lispro et les administrations séparées d’insuline lispro et d’insuline glargine dans une étude de phase 1 chez des sujets diabétiques de type 2” (Poster), Author Dr. Claire Mégret, March 26, 2019, Annual Congress of the Francophone of the Diabetes Society, Marseille (France) Icon check
03/26/2019 “BioChaperone Glucagon, une formulation de glucagon liquide, stable, prête à l’emploi, est bien tolérée et rétablit rapidement la normoglycemie après une hypoglycémie provoquée par infusion d’insuline” (Poster), Author Mr. Aymeric Ranson, March 26, 2019, Annual Congress of the Francophone of the Diabetes Society, Marseille (France) Icon check
03/13/2019 Adocia Announces its Financial Results for 2018: Higher Revenue and Reinforced Cash Position Icon check
Join our mailing list. Subscribe